Telik
| Public | |
| Traded as | NASDAQ:TELK |
| Industry | Drug Manufacturers - Other |
| Founded | 1988 |
| Headquarters | Palo Alto, California, United States |
Key people |
Michael M. Wick M.D. ( Chief Medical Officer ) (Dec 31, 2012) |
Number of employees | 17 (Dec 31, 2012) |
| Website |
www |
Telik, Inc. (NASDAQ:TELK), was set up in 1988 and now is headquartered in Palo Alto, California, a clinical-stage drug manufacturing company. The major drug of the company is TELINTRA, an investigational agent in development for the treatment of myelodysplastic syndrome (MDS) and idiopathic chronic neutropenia.[1]
Products & Services
The company’s preclinical drug is TELINTRA for the treatment of blood disorders, including TLK60404 (inhibiting Aurora and VEGFR kinase), TLK60357 (inhibiting cell division), and TLK60596 (inhibiting the formation of new blood vessels in tumors). TELINTRA has a mechanism by inhibiting GST P1-1, an enzyme to control cellular growth and differentiation. In 2011, the Company initiated a Phase II and an additional Phase IIb clinical trials to evaluate TELINTRA tablets.
Another product is TELCYTA, designed to be activated in cancer cells. The company’s molecule drug candidates are discovered using its target-related affinity profiling (TRAP).[2]
Research & Development
January. 2013, Telik, Inc. achieved the agreement meeting with the US Food and Drug Administration (FDA), allowing the design of a Phase 3 placebo-controlled randomized registration trial of Telintra (ezatiostat) for the treatment of Low to Intermediate-1 risk myelodysplastic syndrome (MDS), using red-blood-cell transfusion independence as the endpoint. [3]
May. 2012, Telik, Inc published two reports in the Journal of Hematology & Oncology. The two publications are “Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)”, “Prediction of response to therapy with ezatiostat in lower risk myelodysplastic syndrome”. [4][5] The company published another two reports,"Oral ezatiostat HCl (Telintra®, TLK199) and Idiopathic Chronic Neutropenia (ICN): A case report of complete response of a patient with G-CSF resistant severe chronic idiopathic neutropenia following treatment with Telintra" in the Journal of Hematology & Oncology and "A Phase 2 Multicenter Study of Two Extended Dosing Schedules of Oral Ezatiostat in Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)" in the Journal Cancer in 2011.[6] [7]
Controversies
In 2007, a class action was filed against Telik, Inc., alleging that they made false and misleading statements about the Company’s business and prospects during the Class Period.[8]
References
- ↑ "Business Summary".
- ↑ "Company Full Description".
- ↑ "Telik Announces Preliminary Agreement On Design Of Phase 3 Registration Trial Of Telintra® In Low To Intermediate-1 Risk Myelodysplastic Syndrome".
- ↑ "Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)" (PDF).
- ↑ "Prediction of response to therapy with ezatiostat in lower risk myelodysplastic syndrome" (PDF).
- ↑ "Oral ezatiostat HCl (Telintra®, TLK199) and Idiopathic Chronic Neutropenia (ICN): a case report of complete response of a patient with G-CSF resistant ICN following treatment with ezatiostat, a glutathione S-transferase P1-1 (GSTP1-1) inhibitor".
- ↑ "A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome".
- ↑ "Lerach Coughlin Stoia Geller Rudman & Robbins LLP Files Class Action Suit Against Telik, Inc.".